Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 59

1.

FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.

Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A.

Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.5471. [Epub ahead of print]

2.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2015 Aug 17. [Epub ahead of print]

PMID:
26278712
3.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.

4.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

5.

In response: Genomic profile of breast cancer.

Seguí MA, Crespo C, Cortés J, Lluch A, Brosa M, Becerra V, Chiavenna S, Gracia A.

Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):395-7. doi: 10.1586/14737167.2015.1025760. Epub 2015 Mar 22. No abstract available.

PMID:
25797142
6.

Are breast cancer patients treated with radiotherapy younger now than ten years ago?

Bonet M, Godoy P, Cambra MJ, Mur E, Algara M, Fernandez L, Dalmau E, Arcusa À, Seguí MÀ, Saigí E, Gonzalez S, Cirera L, Solé JM.

Rep Pract Oncol Radiother. 2014 Jul 17;20(1):22-6. doi: 10.1016/j.rpor.2014.05.003. eCollection 2015 Jan.

7.

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

Seguí MÁ, Crespo C, Cortés J, Lluch A, Brosa M, Becerra V, Chiavenna SM, Gracia A.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12.

PMID:
25213317
8.

Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing.

Ruiz A, Llort G, Yagüe C, Baena N, Viñas M, Torra M, Brunet A, Seguí MA, Saigí E, Guitart M.

Biomed Res Int. 2014;2014:542541. doi: 10.1155/2014/542541. Epub 2014 Jun 26.

9.

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martinez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martin-Fernández M, Mahillo-Fernández I, Tusquets I.

Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7.

PMID:
25108081
10.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.

11.

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors.

Travier N, Fonseca-Nunes A, Javierre C, Guillamo E, Arribas L, Peiró I, Buckland G, Moreno F, Urruticoechea A, Oviedo GR, Roca A, Hurtós L, Ortega V, Muñoz M, Garrigós L, Cirauqui B, Del Barco S, Arcusa A, Seguí MA, Borràs JM, Gonzalez CA, Agudo A.

Med Oncol. 2014 Jan;31(1):783. doi: 10.1007/s12032-013-0783-5. Epub 2013 Dec 6.

PMID:
24310809
12.

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.

Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure Á, Seguí MA, Tredan O, Antón A, Ramos M, Cámara Mdel C, Rodríguez-Martín C, Carrasco E, Alba E.

Breast Cancer Res. 2013 Nov 6;15(6):R105. doi: 10.1186/bcr3572.

13.

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.

Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Review.

PMID:
24071503
14.

[Efficiency of oncologic treatments for solid tumours in Spain].

Oyagüez I, Frías C, Seguí MÁ, Gómez-Barrera M, Casado MÁ, Queralt Gorgas M.

Farm Hosp. 2013 May-Jun;37(3):240-59. doi: 10.7399/FH.2013.37.3.570. Review. Spanish.

15.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):381-91. doi: 10.1586/erp.13.18. Epub 2013 Mar 28.

PMID:
23534988
16.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J.

Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9.

17.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

18.

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.

Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J.

Breast Cancer Res Treat. 2012 Nov;136(2):487-93. doi: 10.1007/s10549-012-2100-y. Epub 2012 Oct 9.

PMID:
23053638
19.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

20.

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margelí M, Arcusa A, Prat A, Garcia M, Borras JM.

Br J Cancer. 2012 Oct 9;107(8):1249-56. doi: 10.1038/bjc.2012.389. Epub 2012 Sep 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk